-
ESMO 2024丨Subgroup Analysis from the ADRIATIC Study Further Supports Durvalumab Consolidation Therapy as a New Standard of Care for Limited-Stage Smal
From September 13 to 17, the 2024 ESMO Annual Meeting is in full swing in Barcelona, Spain. Oncology Frontier is attending the event and bringing you first-hand insights from the conference. During the non-metastatic non-small cell lung cancer (NSCLC) paper session held on September 13, Dr. Suresh Senan from Amsterdam, Netherlands, presented the latest results…
-
CCML 2024丨Dr. Li Gu: Clinical Interpretation and Application of Antimicrobial Susceptibility Reports
Bacterial Resistance Determination There are many types of pathogenic bacteria, each with different inherent and acquired resistance mechanisms, and their susceptibility to various drugs changes dynamically. Additionally, the chemical structure…
-
Dr. Junhong Liu: Advantages and Unique Features of Traditional Chinese Medicine in the Treatment of Liver Fibrosis
Current Status and Limitations of Western Medicine in Treating Liver Fibrosis The primary strategy for treating liver fibrosis in Western medicine is to control and cure the underlying disease and…
-
VITALITY Study Results Announced: Immunotherapy Shows Great Promise as a Neoadjuvant Treatment Before Liver Transplantation in Liver Cancer
ICI works by disrupting inhibitory immune pathways in the tumor microenvironment, reactivating the body’s own antitumor immune responses, and thereby effectively killing tumor cells. This mechanism has allowed ICIs to…
-
The Lancet Gastroenterology & Hepatology: Dr. Qing Xie Leads Global Study on Infections in Hospitalized Cirrhosis Patients Across 24 Sub-centers!
Infection is the most common non-liver-related cause of hospitalization in cirrhosis patients. The global burden of infections and antimicrobial resistance is increasing, with significant regional differences in infection prevention, control,…
-
Isavuconazole for the Treatment of Cerebral Aspergillosis: A Retrospective European EFISG Study
Cerebral aspergillosis (CA) is a lethal invasive fungal infection, with current national and international guidelines recommending voriconazole as the first-line antifungal treatment. While newer triazoles, such as isavuconazole, demonstrate good blood-brain barrier penetration, there is still limited clinical evidence to confirm their efficacy and safety for treating CA. Recently, Clinical Infectious Diseases published a retrospective…
-
Dr. Jianxiang Wang: Leading Research, Continuous Innovation! Focusing on the Practice and Vision of CAR-T Cell Therapy in China
In early September 2024, the 5th Tianjin International Lymphoma Conference was held from September 6 to 8, amid the golden season of autumn. This conference featured 12 specialized sessions, including immunotherapy, basic translational research, and new drug development, creating a high-end academic platform for international exchange and collaboration. During the event, Hematology Frontier invited Dr.…
-
Dr. Wei Sang: Analysis of CAR-T Efficacy and Challenges in Various Hematologic Malignancies at the 5th Tianjin International Lymphoma Conference
From September 6 to 8, 2024, the 5th Tianjin International Lymphoma Conference was successfully held. The conference featured 12 specialized sessions, including immunotherapy, translational research, and new drug development, creating a platform for international academic exchange and cooperation. During the event, Hematology Frontier invited Dr. Wei Sang from The Affiliated Hospital of Xuzhou Medical University…
Connecting Medical Expertise through Media